New research, led by experts at the University of Nottingham, has found that repeated doses of paracetamol in people aged 65 and over, can lead to an increased risk of gastrointestinal, cardiovascular and renal complications.
Read Article
Editor's note: This article originally appeared on August 8, 2024, and is being shared again as a Best of 2024. Enjoy!
Read Article
Editor's note: this article originally appeared August 28, 2024 and is being shared again as a Best of 2024. Enjoy!
Editor's note: this article originally appeared October 7, 2024 and is being shared again as a Best of 2024. Enjoy!
Leiden cohort study of hand osteoarthritis (HOA) patients shows that over 4 years, pain outcomes are variable, and not inevitably worsening.
Editor's note: this article originally appeared August 12, 2024 and is being shared again as a Best of 2024. Enjoy!
This article originally appeared May 15, 2024, and is being shared again as our "Best of 2024". Enjoy!
Read Article
This article originally appeared September 2, 2024, and is being shared again as a "Best of 2024". Enjoy!
Read Article
For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.
Read Article
Editor's note: this article originally appeared July 30, 2024 and is being shared again as a Best of 2024. Enjoy!
Rates of heart failure with preserved ejection fraction (HFpEF) were doubled in patients with rheumatoid arthritis (RA) relative to other people of the same age and sex, researchers found.
Read Article
Editor's note: this article originally appeared February 6, 2024, and is being shared again as a Best of 2024. Enjoy!
Approximately 12 million US adults in the US have gout. Two recent literature reports highlight contributors to gout flares.
Read Article
This article originally appeared February 21, 2024, and is being shared again as a "Best of 2024". Registration for RheumNow Live 2025 is now open - we hope you'll join us in Dallas or as a virtual attendee!
Read Article
Dr. Madelaine Feldman has written an important commentary on the 340B Drug Pricing Program, a safety-net program that would allow vulnerable populations to receive expensive new therapies.
Read Article
This article originally appeared April 1, 2024, and is being shared again as a "Best of 2024". Enjoy!
Read Article
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
This article originally appeared March 11, 2024, and is being shared again as a "Best of 2024". Enjoy!
Read Article
Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these products -- even though biosimilars barely dented Humira prescription rates.
Read Article
Editor's note: this article originally appeared February 19, 2024 and is being shared again as a Best of 2024. Registration for RheumNow Live 2025 is open, and we hope you'll join us. Enjoy!
Read Article
A Spanish Collaborative Group study of Tocilizumab (TCZ) in Giant Cell Arteritis (GCA) demonstrated high efficacy regardless of the different vascular phenotypes treated.
